MCRN 003 – The KCd Trial
Carfilzomib (Kyprolis®) is a new proteasome inhibitor that was approved by Health Canada in January 2016, but is not yet funded by any provincial drug plan. The KCd Trial provides access to this new drug to eligible patients with the triplet combination of carfilzomib, cyclophosphamide and dexamethasone. Cyclophosphamide is believed to have immunomodulatory properties and provides a more cost-effective alternative to other carfilzomib triplet combinations that have been studied.
The currently approved dosing schedule for carfilzomib is twice weekly. The trial is evaluating a once-weekly dosing regimen that will is more convenient for the patient and is also more cost-effective. The overall lower cost of this combination may help influence provincial drug funding decisions in the future.
The trial is being led by Dr Christopher Venner from the Cross Cancer Institute in Edmonton.
As of January 31, 2018, 76 patients out of a planned total of 76 have been recruited, and the trial is now closed.
A special mention goes to the Cross Cancer Institute, Maisonneuve-Rosemont Hospital and the Ottawa Hospital Research Institute who collectively accounted for more than half of total patient accrual.
- Edmonton – Cross Cancer Institute
- Halifax – Queen Elizabeth II Health Sciences Centre
- Kingston – Kingston General Hospital
- London – London Health Sciences Centre
- Montreal – Maisonneuve-Rosemont Hospital
- Ottawa – The Ottawa General Hospital
- Quebec City – Pavillon Hôtel-Dieu de Québec
- Saint John – Saint John Regional Hospital
- Toronto – Princess Margaret Cancer Centre